EQ

Equillium, Inc.

2.39 USD
-0.15 (-5.91%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Equillium, Inc. stock is up 187.95% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 February’s closed higher than January.

About Equillium, Inc.

Equillium, Inc. develops and sells products to treat severe autoimmune and inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6.